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ABSTRACT
Background: The most frequent pancreatic tumours are derived from insulin-secreting β cells, commonly called in-
sulinomas; these are characterised by high insulin secretion causing hypoglycemia and clinical signs such as seizures, 
tremors, weakness, and polyphagia, among others. In dogs, this tumour represents <0.5% of neoplasias; the majority are 
solitary carcinoma masses and rarely adenomas. Insulin-secreting tumours are usually diagnosed in middle-aged or older 
dogs. There is no apparent sex predilection for the disease and it has been mainly reported in medium to large breeds. 
Independently of whether they are adenomas or carcinomas, dogs have the same disease-free time and survival time and 
the prognosis is poor. 
Case: An 8-year-old female Boxer was brought to the University Veterinary Hospital with a history of weakness, tremors, 
and generalised convulsions. Physical examination, CBC and urinalysis revealed no abnormalities. In the blood chemistry 
profile, hypoglycemia was detected along with hyperinsulinemia. An abdominal ultrasound revealed the presence of two 
abnormal masses located in the pancreas. The insulin:glucose ratio was 59.8. Exploratory celiotomy was performed and 
two masses were located in the mesentery, adjacent to the left pancreatic lobe, and a third was in the pancreatic tissue of 
the same lobule. All masses were resected during the same surgery. Cytology of the masses coincided with apparently 
malignant insulinoma, however, the histopathological and immunohistochemically report indicated an insulin-secreting 
adenoma. The patient improved clinically and remained stable for approximately 545 days, after which seizures relapsed 
and a new treatment was not approved. The patient died 575 days after surgery. 
Discussion: In dogs, pancreatic islet cell tumours correspond to endocrinologically active neoplasm that secrete hormones 
and are associated with functional disorders (hyperinsulinemia) in relation to hypoglycemia. Hypoglycemia causes episodic 
signs that are generally observed for a few seconds to several minutes, because of regulatory compensatory mechanisms. 
In animals, rapid hypoglycaemia activates the sympathetic nervous system via hypothalamic glucoreceptors, producing 
signs such as tachycardia, tremors, nervousness, irritability, and intense hunger. Other clinical signs are related to neuro-
glycopenia by a decrease in blood glucose, which stimulates the autonomic nervous system, causing hypothermia, lethargy, 
weakness, ataxia, collapse, muscular fasciculation, convulsions, and coma. The diagnosis of an insulin-secreting tumour 
requires confirmation of hypoglycemia with evidence of elevated insulin secretion and the identification of a pancreatic 
mass by ultrasonography or exploratory celiotomy. An insulin:glucose ratio >30 is indicative of insulinoma. Unfortu-
nately, the specificity of the amended insulin:glucose ratio is poor. In the past, there has been confusion with respect to 
their biological nature, because, based on histological and electron microscopic evaluations, 60% of these neoplasms are 
carcinomas and 40% are adenomas. Nevertheless, these claims were not substantiated and most insulinomas are currently 
considered to be malignant (carcinomas). The objective of this paper was to present a rare case of a Boxer dog that had 
three β cell tumours of the pancreas, which produced hyperinsulinemia and hypoglycemia. Although this is not a malignant 
tumour, we demonstrated, as described in the literature, that regardless of the histopathological classification, insulin-
producing tumours have a poor prognosis in dogs.
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 INTRODUCTION
Insulinoma is the most frequent pancreatic 
tumour from insulin-secreting β cells [9,15]. In 90% 
of cases, the tumour is a small, solitary, endocrinologi-
cally-active nodule, causing hypoglycemia secondary 
to hyperinsulinemia [18]. In the past, 60% of these 
neoplasms were considered to be carcinomas and 40% 
were adenomas. However, insulinomas are considered 
to have a high malignancy component [20].
Insulinoma is usually diagnosed in middle-
-aged or older dogs of medium to large breeds, such 
as Standard Poodles, Boxers, German Shepherds and 
Irish Setters, although it may occur in any breed [6,16]. 
The diagnosis of an insulin-secreting tumour requires 
confirmation of hypoglycemia, evidence of increased 
insulin secretion, and identification of a pancreatic 
mass by ultrasonography or exploratory celiotomy 
[13,21]. An insulin:glucose ratio >30 is indicative of 
insulinoma. Unfortunately, the specificity of this test is 
poor because dogs with other causes of hypoglycemia 
can also have abnormal ratios [3].
Partial pancreatectomy is the elective treat-
ment; however, in animals with metastatic disease, 
surgery should only be performed for palliative reasons 
[10]. Median survival time of dogs treated with this 
surgery is 785 days. Dogs treated medically have a me-
dian survival of 196 days, and medically and surgically 
treated dogs have a median survival of 1316 days [16]. 
The aim of this study is to present a rare 
case of a Boxer dog that had three pancreatic β cell 
adenomas, which produced hyperinsulinemia and 
hypoglycemia. We demonstrated, as described in 
the literature, that regardless of the histopathological 
classification, insulin-producing tumours have a poor 
prognosis in dogs.
CASE
An 8-year-old spayed female Boxer presented 
to the clinic for examination. The patient was spayed 5 
years prior and her vaccination and deworming calen-
dars were up to date. The patient lived with two other 
clinically-healthy dogs. Water and food consumption 
were normal, and she had normal micturition and def-
ecation. Previous diseases were not reported.
The animal had three seizures over the previous 
three days. In addition, she showed a predromal period: 
nervousness, weakness and trembling, after which she 
presented with generalised tonic-clonic seizures and a 
loss of consciousness for 1 to 3 min, from which she 
reincorporated confused; after 5 to 10 min, she recovered 
completely, returning to a normal physical and mental 
state. On previous occasions (external veterinary clinic), 
the bitch had presented with hypoglycemia at 0.59 and 
2.49 mmol/L (ranging from 3.9 to 6.64 mmol/L).
During the physical examination, the patient 
was alert and responsive to external stimuli; she 
showed a body condition of 4/5, according to the 
scale of Laflamme [5], and had a body weight of 42 
kg. Her physiological parameters were within normal 
ranges. No significant abnormalities were reported in 
the CBC and urinalysis. Contrarily, the biochemical 
analysis, reported hypercholesterolemia (7.8 mmol/L, 
ranging from 3.12 to 6.18 mmol/L). Additionally, the 
animal presented with hyperproteinaemia (81 g/L, 
ranging from 56.6 to 54.3 g/L), hyperphosphatemia 
(2.00 mmol/L, ranging from 0.78 to 1.72 mmol/L), 
hypoglycaemia (3.50 mmol/L, ranging from 3.90 to 
6.64 mmol/L) and a slightly elevated ALT (87 U/L 
range <70 U/L) and ALP (410, range <189 U/L). The 
dog had hyperinsulinemia (89.75 ranging from 5 to 20 
mU/L), even after fasting. Finally, the insulin:glucose 
ratio was 59.8 (normal <30). An abdominal ultrasound 
(mode B) revealed a 0.6 x 0.86 cm hypoechoic mass 
on the left pancreatic lobe (Figure 1) and another hy-
poechoic mass near the same lobe. 
The dog’s owner was told to feed the patient 4 
to 6 times a day with her normal diet, and if the trem-
bling and nervousness were detected again, to orally 
administer honey as a source of glucose. The animal 
was referred to surgery for an exploratory celiotomy 
with the presumptive diagnosis of insulinoma. Before 
the surgery, slight hypoglycemia was reported (3.38 
mmol/L ranging from 3.90 to 6.64 mmol/L). A 5-mL 
bolus of glucose at 50% was administered as described 
in the literature [11] and the animal was maintained on 
a continuous intravenous administration of fluids with 
5% dextrose in Hartmann solution (Solución Combi-
nación P.I.®)1. Glucose peri-surgical monitoring was 
performed and normal values were reported. 
During the exploratory celiotomy, two mesen-
teric masses next to the pyloric antrum and adjacent to 
the left pancreatic lobule were detected and removed 
(1.7 x 1.5 cm and 2 x 1.3 cm). During the same surgery, 
a third mass was localised and resected from the left 
pancreatic lobule (1.1 x 0.7 cm) [Figure 2]. There was 
no macroscopic evidence of metastases in the liver, 
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lymph nodules, or other organs. Fine-needle aspira-
tion (FNA) of mesenteric lymph nodules did not show 
diagnostic material.
After surgery, glucose concentration was 
monitored every 30 to 60 min for the first 4 to 6 h, 
and then every 2 to 4 h until glucose concentration 
stabilised. The animal fasted for 72 h post-surgery, 
and was administered ampicillin (22 mg/kg IV every 
8 h [Pentrexyl®]2), enrofloxacin (2.5 mg/kg IV every 
12 h [baytril®]3) and a fluid therapy of 5% dextrose 
in Hartmann solution, alternating with 0.9% NaCl 
(Solución CS-PiSA®)1 at maintenance doses. 
Postsurgical testing and clinical evolution
Four days after surgery, the dog went home. 
Blood glucose and serum insulin were measured 30 
days post-surgery, resulting in normal values: 4.4 
mmol/L blood glucose, ranging from 3.9 to 6.64 
mmol/L, and 35.62 mU/L insulin, ranging from 5 to 20 
mU/L. At this time, the insulin:glucose ratio was 7.22. 
The patient remained healthy until 560 days 
after surgery, after which she presented with episodes 
of seizures. The owner decided not to administer treat-
ment for this new episode of seizures, resulting in the 
death of the patient at 575 days after surgery. 
The histopathology results for the three masses 
were insular endocrine adenomas, which, in immuno-
histochemistry analyses, showed a strong and diffuse 
immunoreaction to insulin. 
DISCUSSION
In humans and dogs, although rare, insulino-
mas are the most frequent pancreatic functioning islet 
cell tumours. These tumours produce signs related 
to hyperinsulinism, producing hypoglycemia, which 
is episodic and generally last from seconds to a few 
minutes due to regulatory compensatory mechanisms 
[3,8,14,21]. In dogs, clinical signs occur due to glucose 
deprivation of the central nervous system, which are 
categorised as neuroglycopenic symptoms. However, 
there are a number of adrenergic signs caused by ca-
techolamines; dogs can display a combination of these 
signs [11]. Signs related to neuroglycopenia, which 
stimulates the autonomic nervous system, are hypo-
thermia, lethargy, weakness, ataxia, collapse, muscular 
fasciculation, convulsions, and coma. If there is a fast 
decrease in blood glucose, hypothalamic glucorecep-
tors activate the sympathetic nervous system, produ-
cing signs such as tachycardia, tremors, nervousness, 
irritability, and intense hunger [3,21]. Generally, the 
most common sign in dogs with insulinoma is seizures 
[11]. Clinical signs are intermittent and they become 
more frequent as the disease progresses [21]; these 
signs are usually episodic and glucose administration 
quickly relieves them [11,12]. This is consistent with 
the present case, where the owner identified the seizure 
predromal phase, reporting the presence of episodes 
of tremors, nervousness, weakness, and generalised 
convulsions; these ceased to be present once glucose 
in the form of honey was administered to the patient, 
suggesting that the signs were due to hypoglycemia. 
As in this clinical case, physical examination 
is unremarkable in most dogs with insulinomas. Obe-
sity (4/5 body condition) was the only significant ab-
normality found in the general physical examination; 
excess weight has been described as being due to the 
Figure 1. Ultrasonographic detection of a hypoechoic mass in the patient’s 
left pancreatic lobe, delimited by the cross symbols (the white arrow points 
to the duodenum, transverse section).
Figure 2. Perioperative photograph of a nodule localized in the left pan-
creatic lobule.
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anabolic effects of insulin, and the postictal effects 
in dogs with seizures [4,17]. 
The diagnosis of an insulin-secreting tumour 
requires confirmation of hypoglycemia, evidence of 
increased insulin secretion and identification of a pan-
creatic mass by ultrasonography or exploratory celio-
tomy [21].  An insulin:glucose ratio >30 is indicative 
of insulinoma. However, this test has low specificity 
because animals with hypoglycemia secondary to other 
causes could also have abnormal ratios [3]. In the pre-
sent case, the test was efficient due to the evidence of 
hypoglycemia, which stabilised after the administration 
of honey; in addition, the initial insulin:glucose ratio 
was 59.8, and the ultrasound helped to identify the 
presence of masses in the pancreas, which justified the 
exploratory celiotomy, with a presumptive diagnosis 
of an insulin secreting β cell tumour. This diagnosis 
was confirmed by the exploratory celiotomy and the 
histopathologic evaluation of the excised tissue.
Treatment for insulinomas should be directed 
to specific treatment for the tumour (surgical resec-
tion), reduction of the secretion of insulin and correc-
tion of hypoglycemia [12]. Treatment can be medical 
or surgical. Drugs such as prednisolone, diazoxide, 
octreotide and streptozotocin may be used as medical 
treatments for this disease [17]. Surgical resection of 
the pancreatic tumour and metastatic tumour masses 
is the treatment of choice; however, many animals 
present with evidence of metastatic disease at the time 
of the celiotomy and, in these cases, surgery should 
only be performed for palliative reasons [19]. In this 
case, exploratory celiotomy was chosen and no ma-
croscopic evidence of metastases were found during 
the surgery. However, the dog had multiple masses, 
which is unusual as 75% of cases have been described 
as having a solitary tumour [7]. Dogs with insulinoma 
who underwent a partial pancreatectomy showed a 
median survival time of 785 days; dogs only treated 
medically had a median survival (MTS) of 196 days, 
whereas medically and surgically treated dogs had 
a MTS of 1316 days [6,16]. In this case, the patient 
remained clinically healthy until 560 post-surgical 
days, after which time clinical seizures relapsed, and 
she died at 575 days after surgery; this period of time 
is slightly less than average.
Prognosis for insulinoma is reserved because 
more than 95% of canine insulinomas are malignant 
and metastatic disease is already present in most pa-
tients at the time of surgery [9]. Metastatic disease can 
be evaluated in two ways: macroscopic examination of 
the target organs during an exploratory celiotomy (liver 
and lymph nodules), or blood glucose stabilisation after 
surgery and after glucose infusion has been stopped 
[1]. However, even in a normal gross inspection, the 
liver and lymph nodes should be biopsied [11]. One 
limitation of this clinical case is that the target organs 
were not biopsied and the FNA for cytology was not 
diagnosed. However, as the dog had a final diagnosis 
of adenoma, it is unlikely to have metastasised, but the 
histopathological classification of the tumour was not 
important in this case; the prognosis and survival of 
dogs with insulinoma is similar in cases of carcinomas 
or adenomas. 
In dogs, the classification of insulinomas as 
benign or malignant is based on their morphology. 
Pancreatic β cell tumours are typically divided into 
adenomas or adenocarcinomas, but frequently, this 
division does not reflect their biological behaviour 
because the disease-free interval and survival time 
have been shown to be equivalent in dogs with 
adenomas and adenocarcinomas. Although histopa-
thological studies remain important, the prognostic 
markers for canine insulinomas are tumour size, 
TNM stage (lymph node involvement and distant 
metastasis), presence of necrosis, and nuclear 
atypia [2].  In addition, an immunohistochemical 
biomarker, the Ki67 index, has proven to be an 
effective prognostic marker for canine insulinomas. 
Therefore, this biomarker and tumour size (>2 cm) 
are particularly influential parameters to determine 
patient survival [1,2]. In the present case, the animal 
presented with three tumours, and only one was >2 
cm, so it was classified as stage II. 
Insulinomas are rare neoplasms in dogs, 
however, in cases of adult animals with a history of 
seizures, extracranial causes must be suspected, such 
as hypoglycemia secondary to this tumour. The signs 
of insulinomas are varied and nonspecific, and there 
are several tests to confirm or rule out the condition, 
including measuring serum glucose and insulin and 
determining the insulin:glucose ratio. However, a de-
finitive diagnosis is made by exploratory celiotomy, 
resection of the tumour and the histopathological 
analysis of the tumour. Partial pancreatectomy is the 
treatment of choice, even if it is only palliative. 
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Finally, a rare case of a pancreatic β cell ad-
enoma producing hyperinsulinemic hypoglycemia is 
presented. This has demonstrated a phenomenon that 
has been previously established: in insulinomas, the 
biological behaviour of malignant or benign tumours is 
similar, with both having the same reserved prognosis, 
disease-free time and equal short-term survival.
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